SEC Filing Summary: Amedica Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Amedica Corporation on January 24, 2017, reporting events occurring on the same date. The filing details the closing of a previously announced underwritten public offering.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial event reported is the issuance of equity and warrants:
- Common Stock Issued: 8,900,000 shares
- Warrants Issued: Warrants to purchase 4,005,000 shares of common stock
- Warrant Agent: American Stocker Transfer & Trust Co. (AST)
Material Changes
The material change reported is the successful closing of the public offering on January 24, 2017. This resulted in an increase in the company's outstanding share count and the creation of new warrant obligations. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the warrant agency agreement. The document focuses solely on the execution of the offering and the appointment of the warrant agent.
Investor Verification Checklist
- Verify the final offering price per share and total gross proceeds raised, as these figures are not explicitly stated in this specific 8-K text.
- Review the attached Warrant Agency Agreement (Exhibit 10.1) for exercise prices, expiration dates, and conversion terms of the 4,005,000 warrants.
- Confirm the updated total number of outstanding shares and potential dilution impact on existing shareholders.
- Check subsequent filings for the use of proceeds from this offering.